Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk-Reference-Cited by-同舟云学术

Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk

Published:2018-01 Issue:1 Volume:12 Page:130-136
ISSN:1933-2874
Container-title:Journal of Clinical Lipidology
language:en
Short-container-title:Journal of Clinical Lipidology

Author:

Arsenault Benoit J.,Petrides Francine,Tabet Fatiha,Bao Weihang,Hovingh G. Kees,Boekholdt S. Matthijs,Ramin-Mangata Stéphane,Meilhac Olivier,DeMicco David,Rye Kerry-Anne,Waters David D.,Kastelein John J.P.,Barter Philip,Lambert Gilles

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference44 articles.

1. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins;Baigent;Lancet,2005

2. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels;Marais;Pharmacol Ther,2015

3. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia;Dubuc;Arterioscler Thromb Vasc Biol,2004

4. Proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial;Awan;Clin Chem,2012

5. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events;Robinson;N Engl J Med,2015

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metformin-induced PCSK9 inhibition further decreases LDL-C following statin treatment in patients with coronary artery disease and without diabetes;Journal of Cardiovascular Pharmacology;2024-05-21

2. PCSK9 plasma concentration is associated with epicardial adipose tissue volume and metabolic control in patients with type 1 diabetes;Scientific Reports;2024-03-26

3. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?;International Journal of Molecular Sciences;2024-03-21

4. Geranylgeranyl isoprenoids and hepatic Rap1a regulate basal and statin-induced expression of PCSK9;Journal of Lipid Research;2024-03

5. Espoirs et place prochaine potentielle des inhibiteurs de la Lp(a);Archives des Maladies du Coeur et des Vaisseaux - Pratique;2024-03